Jefferies Comments On Albany Molecular Rsrch Growth Focus

According to Jefferies, Albany Molecular Rsrch AMRI continues to focus on growth opportunities outside the U.S. while recapturing business at home. Jefferies said that Allegra royalties got a significant boost but not enough to produce a profitable quarter. “Issues surrounding the Burlington facility are moving toward resolution in the next couple quarters allowing resumption of selling efforts. In the meantime, cash balances provide a limited cushion against shocks.” Albany Molecular Rsrch closed yesterday at $5.34.